- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Team- and System-Based Approaches to Managing LEMS and Ensuring Access
A panelist discusses how comprehensive care coordination between specialists, proactive adverse effect management, and innovative care models can optimize treatment outcomes for Lambert-Eaton myasthenic syndrome (LEMS) patients, particularly those with dual diagnoses like small cell lung cancer (SCLC), while ensuring both clinical effectiveness and cost-efficiency through managed care strategies.
EP: 1.LEMS and SCLC: Unraveling the Neuromuscular-Cancer Connection
EP: 2.Strategies to Alleviate the Clinical and Economic Burden of LEMS
EP: 3.The Clinical and Economic Impact of LEMS in SCLC Care
EP: 4.Using Technology for Early Detection of LEMS
EP: 5.Team- and System-Based Approaches to Managing LEMS and Ensuring Access
EP: 6.The Role of Patient Engagement Tools and Patient Advocacy Groups in LEMS Care
EP: 7.Managed Care Partnerships and Continuity of Care
Video content above is prompted by the following:
- How can health care teams proactively manage adverse effects associated with treatments like amifampridine?
- How can managed care organizations facilitate timely access to LEMS therapies while ensuring cost-effectiveness?
- What strategies can improve communication and coordination between oncologists, neurologists, and pharmacists in managing dual-diagnosis patients?
- What innovative care models have shown promise in improving outcomes for patients with dual diagnoses like SCLC and LEMS?
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More
